Aligos 10-Q: $31.1M Cash Funds Operations Only Into Q1 2027, Going Concern Flagged
ALGS is trading near its 52-week low of $3.98 (12% above the low).
Summary
Aligos closed Q3 with $31.1 million in cash — enough to fund operations only into Q1 2027 — and flagged substantial doubt about its ability to continue as a going concern, with the key Phase 2 HBV data not expected until late Q3 2027.
Key Events · Earnings and Guidance · ALGS
-
Going Concern Warning on Thin Runway
Cash and cash equivalents of $31.1 million at September 30, 2026 are expected to fund planned operations only into Q1 2027 — less than 12 months from the filing date — raising substantial doubt about the company's ability to continue as a going concern.
-
Q3 Loss Narrows but Comparison Misleading
Q3 2026 net loss was $21.9 million ($2.09 per share) versus $31.5 million ($3.04) a year earlier; the nine-month loss widened to $46.4 million from $4.3 million because 2025 included a $58.97 million non-cash warrant remeasurement gain.
-
Amoytop Upfront Is the Only Real Inflow
The May 2026 Greater China license for pevifoscorvir sodium brought a $25.0 million upfront (net of Chinese withholding tax), received in July 2026 and recognized as $27.8 million of licensing revenue in the nine months, against up to $420 million in milestones.
-
Warrant Remeasurement Is Non-Cash
The $6.56 million nine-month gain on the 2023 common warrants cut the liability to $5.6 million from $12.2 million; this is a mark-to-market accounting entry tied to the share price, not dilution, new warrants or cash.
Analysis · ALGS · Life Sciences
The headline loss is smaller than a year ago, but that comparison is misleading: last year's nine-month figure was flattered by a $59.0 million non-cash warrant remeasurement gain that did not repeat. Liquidity is the real story. Aligos ended September with $31.1 million in cash and no short-term investments, down from $77.8 million at year-end, and management states plainly that this funds operations only into the first quarter of 2027 — less than twelve months out — raising substantial doubt about the company's ability to continue as a going concern. The only meaningful cash inflow was the $25.0 million Amoytop upfront for Greater China rights to pevifoscorvir sodium, already received in July. With the Phase 2 B-SUPREME topline not due until late Q3 2027, the company must raise capital before that readout, and any equity raise would come at a share price far below the $18.92 and $26.02 strikes on its outstanding warrants.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALGS was trading at $4.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $3.98 to $13.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.